Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00047567
NCT00047567TerminatedPhase 4

Open-label Adjunctive Zonisamide for Bipolar Disorder

Elan Pharmaceuticals0 sites20 target enrollmentStarted: July 1, 2002Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Terminated
Enrollment
20
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
6 Years to 17 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Bipolar I/II
  • •Average intelligence
  • •Taking at least one, but no more than two mood stabilizers

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Industry

Similar Trials

Completed
Phase 3
Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial SeizuresPartial Seizures
NCT00327717Eisai Inc.240
Terminated
Phase 3
Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised EpilepsyEpilepsy
NCT00693017Eisai Limited10
Completed
Phase 4
Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial EpilepsyEpilepsy
NCT01140867Eisai Korea Inc.121
Completed
Phase 3
A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study)Partial Seizures
NCT01136954Eisai Limited144
Completed
Phase 3
A Study of Zonisamide to Prevent Olanzapine-Associated Weight GainWeight Gain
NCT00363376Lindner Center of HOPE42
Open-label Adjunctive Zonisamide for... | Clinical Trial